None
EN
Comment on Series B Funding Helps Dutch Biotech Fight Graft Versus Host Disease by StefanG
StefanG
Comments for Labiotech.eu
Great overview, however, I am missing Kiadis Pharma here. They are quite advanced in phase 3 now and their technology is simply elegant. Conditional approval could be by end of this year already so that they are leading in this field.